Drug Trial Radar · NCT07522151
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
874
Planned (sponsor's estimate)
Start
May 7, 2026
Primary completion
Dec 2029
Study completion Feb 2034
Sponsor
- Lead sponsor
- Shanghai Shengdi Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.
Conditions
- Locally Advanced Gastric or Gastroesophageal Junction Cancer
Interventions
Adebrelimab plus S-1 and oxaliplatinDrug
Adebrelimab plus S-1 and oxaliplatin
Adebrelimab blank preparation plus S-1 and oxaliplatin.Drug
Adebrelimab blank preparation plus S-1 and oxaliplatin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed EFSTime frame: About 8 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.